RTKi revolutionised the treatment of BCR-ABL1-positive chronic myeloid leukaemia, human epidermal growth factor receptor 2 (HER2)-positive breast cancer, and epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC) [14]. This evidence concerns the gene ERBB2 and chronic myelogenous leukemia, BCR-ABL1 positive.